Bio-Techne Corporation has released a corporate presentation highlighting its focus on purposeful innovation to advance science and medicine. The company, a leader in proteomics for 48 years, outlines its differentiated portfolio that serves high-growth markets. The presentation details their segments and product portfolio, including Protein Sciences, Cell Therapy, Diagnostics, and Spatial Biology. Bio-Techne reported FY2024 revenues of approximately $1.2 billion, with a significant portion derived from consumables. The company operates globally with headquarters in Minneapolis, MN, employing around 3,100 people across 34 worldwide locations. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。